drugset / Trial / NCT00782821
Randomized Trial of Induction Therapies in High Immunological Risk Kidney Transplant Recipients
Phase 4
Completed
40 enrolled
University of Cincinnati
Genzyme, a Sanofi Company · collabMillennium Pharmaceuticals, Inc. · collab
RandomizedParallel-groupOpen-labelPrevention
Summary
The purpose of this research study is to find out the effects of adding B lymphocyte modulating agents in patients at risk for rejection receiving an anti-rejection (immunosuppressive) regimen of Thymoglobulin® induction with Prograf®, Cellcept® and corticosteroid therapy.
Timeline
- Start
- 2008-09
- Primary completion
- 2013-02
- Completion
- 2013-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bortezomib | Small molecule | 1.3 mg/m2 | Intravenous |
| Subject | Rituximab | Monoclonal antibody | 200 mg/m2 | Intravenous |
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | Intravenous |
| Subject | Thymoglobulin | Protein / enzyme biologic | 1.5 mg/kg | Intravenous |
Indications
No indication recorded.